Randomized (N=1001)

Excluded (not meeting inclusion criteria) (n=11)
- M1 disease (n=4)
- Bilateral breast cancer (n=1)
- Co-existing renal cancer (n=1)
- Inadequate examination of lymph nodes (n=1)
- Violation in randomization procedure (n=4)

Eligible (N=990)

Arm A: E-T-CMF
Allocated to intervention (n=333)
- Received allocated intervention (n=325)
- Changed to Arm B (n=2)
- Changed to Arm C (n=5)
- Never starters (n=1)

As treated
Completed treatment (n=308)
Discontinued (n=19)
Never started (n=1)
Evaluable for toxicity (n=326)

Intent-to-treat
Progressed (n=51)
Dead (n=31)
Still on follow-up (n=299)
Lost to follow-up (n=3)

Arm B: E-CMF-wD
Allocated to intervention (n=331)
- Received allocated intervention (n=312)
- Changed to Arm A (n=1)
- Changed to Arm C (n=17)
- Never starters (n=1)

As treated
Completed treatment (n=275)
Discontinued (n=42)
Never started (n=2)
Evaluable for toxicity (n=316)

Intent-to-treat
Progressed (n=39)
Dead (n=23)
Still on follow-up (n=301)
Lost to follow-up (n=7)

Arm C: E-CMF-wT
Allocated to intervention (n=326)
- Received allocated intervention (n=320)
- Changed to Arm A (n=1)
- Changed to Arm B (n=3)
- Never starters (n=2)

As treated
Completed treatment (n=291)
Discontinued (n=51)
Never started (n=1)
Evaluable for toxicity (n=320)

Intent-to-treat
Progressed (n=37)
Dead (n=30)
Still on follow-up (n=294)
Lost to follow-up (n=2)

Combined arms (n=657)